

Sareum Holdings

Healthcare

23 June 2026

Peer-reviewed validation for SDC-1801

Sareum has announced the publication of full Phase I clinical data for lead asset SDC-1801 (a TYK2/JAK1 inhibitor) in the *British Journal of Clinical Pharmacology*. We view the publication as an external validation of the programme, providing peer-reviewed confirmation of the safety, pharmacokinetic (PK) and pharmacodynamic (PD) profile previously reported by management. Importantly, the data support the potential for once-daily oral dosing and demonstrate clear target engagement of both TYK2 and JAK1. This reinforces Sareum's positioning of SDC-1801 as a differentiated therapy for autoimmune diseases. The publication also supports the company's ongoing Phase II-enabling activities (including formulation optimisation and the ongoing toxicology studies), with management targeting completion of the regulatory package by end-CY26.

The peer-reviewed paper confirms previously reported results by the company, providing independent validation of SDC-1801's clinical potential. The Phase I study was a randomised, single-centre trial designed to assess the safety, tolerability and PK/PD of various doses of SDC-1801 versus placebo. The study demonstrated a favourable safety profile, with doses ranging from 5mg to 150mg generally well tolerated, no deaths and no treatment-related serious adverse events reported, although one participant experienced treatment-related rhabdomyolysis in the 100mg cohort. This favourable safety profile is particularly meaningful given the historical concerns around less selective JAK inhibitors.

From a PK perspective, SDC-1801 demonstrated a half-life of approximately 15–27 hours, supporting once- or twice-daily dosing. Multiple-dose administration reduced inflammatory biomarkers, including interferon gamma-induced protein 10 (IP-10) and high-sensitivity C-reactive protein (hsCRP), alongside concentration-dependent inhibition of STAT3 and STAT5 phosphorylation, providing direct evidence of TYK2/JAK1 pathway engagement. Notably, computational modelling suggested that a 70mg twice-daily regimen achieved exposure levels comparable to Pfizer's TYK2/JAK1 inhibitor brepocitinib (currently under FDA review for dermatomyositis), but without evidence of the haematological or renal effects observed with brepocitinib. While cross-trial comparisons should be interpreted cautiously, we believe the findings support management's view that SDC-1801 may offer a differentiated efficacy-safety profile within the TYK2/JAK1 class.

Notably, the PK findings observed some differences in exposure between capsule strengths, which we believe has informed Sareum's previously announced formulation optimisation programme. Management expects this work, alongside the ongoing toxicology programme, to support a complete Phase II-enabling package by end-2026. We believe successful completion should strengthen Sareum's position in future partnering discussions as SDC-1801 advances towards Phase II.


Historical financials

Year end	Revenue (£m)	PBT (£m)	EPS (p)	P/E (x)
6/22	0.0	(2.6)	(3.20)	N/A
6/23	0.0	(4.0)	(4.70)	N/A
6/24	0.0	(4.6)	(4.20)	N/A
6/25	0.0	(4.9)	(3.60)	N/A

Source: Company data. Note: PBT and EPS are as reported.

Price 23.00p
Market cap £32m

Share price performance



Share details

Code	SAR
Listing	AIM
Shares in issue	138.6m
Net cash/(debt) at 31 December 2025	£2.5m

Business description

Sareum Holdings is a UK-based company specialising in small molecule kinase inhibitors. Its lead programmes are TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is expected to be Phase II-ready by Q4 CY26. Other programmes include the CHK1 inhibitor SRA737, for which Sareum acquired the licence in March 2025, corresponding to a 63.5% economic interest (27.5% held previously).

Bull points

- SDC-1801's dual TYK2/JAK1 selectivity provides a competitive edge to peers, pending clinical validation.
- First-in-class potential for SDC-1802 and SRA737 in multiple cancer indications.
- Approval of Sotyktu provides regulatory feasibility for TYK2 inhibitors.

Bear points

- Potential funding challenges due to partnering delays affecting clinical progress of assets.
- Safety/efficacy profile of TYK2/JAK1 inhibitors needs to be proved in larger trials.
- Markets sought by SDC-1801 and SDC-1802 are highly competitive.

Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

Sareum Holdings is a research client of Edison Investment Research Limited

General disclaimer and copyright

This report has been commissioned by Sareum Holdings and prepared and issued by Edison, in consideration of a fee payable by Sareum Holdings. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.